Mepolizumab and eosinophil-mediated disease

Current Medicinal Chemistry

Volumn 16, Issue 36, 2009, Pages 4774-4778

  Walsh, G M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asthma; Eosinophilic esophagitis; Eosinophils; Hypereosinophilic syndrome; IL 5; Mepolizumab

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 5; MEPOLIZUMAB; PLACEBO; PREDNISONE; RESLIZUMAB;

ALLERGIC ASTHMA; ASTHMA; ATOPIC DERMATITIS; CELL ACTIVITY; CELLULAR IMMUNITY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; EOSINOPHIL; EOSINOPHILIC ESOPHAGITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOEFFLER PNEUMONIA; NONHUMAN; NOSE POLYP; RESPIRATORY TRACT INFLAMMATION; REVIEW; UNSPECIFIED SIDE EFFECT; WELLS SYNDROME;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; EOSINOPHILIA; EOSINOPHILS; ESOPHAGITIS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5;

EID: 71949107298     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789909639     Document Type: Review

References (46)

1. Walsh, G.M. Advances in the immunobiology of eosinophils and their role in disease. Crit. Rev. Clin. Lab. Sci. 1999, 36, 453-496. (Pubitemid 29535220)
2. Blanchard, C.; Rothenberg ME. Biology of the eosinophil. Adv. Immunol., 2009, 101, 81-121.
3. Foster, P.S.; Hogan, SP; Ramsay, A.J.; Matthaei, K.I.; Young, I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 1996, 183, 195-201.
4. Iwamoto, T; Takatsu, K. Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Int. Arch. App. Immunol., 1995, (Suppl 1), 28-30.
5. Takatsu, K; Nakajima, H. IL-5 and eosinophilia. Curr. Opin. Immunol., 2008, 20, 288-294
6. Flood-Page, P.; Swenson, C.; Faiferman, I.; Matthews, J.; Williams, M.; Brannick, L.; Robinson, D.; Wenzel, S.; Busse, W.; Hansel, T.T.; Barnes, N.C. International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med., 2007, 176, 1062-1071
7. MacKenzie, J.R.; Mattes, J.; Dent, L.A.; Foster, P.S. Eosinophils promote allergic disease of the lung by regulating CD4 + Th2 lymphocyte function. J. Immunol., 2001, 167, 3146.
8. Wang, H.-B.; I. Ghiran, I: Matthaei, K.; Weller, P.F. Airway eosinophils: allergic inflammation recruited professional antigenpresenting cells. J. Immunol., 2007, 179, 7585-7592.
9. Jacobsen, E.A.; Ochkur, S.I.; Pero, R.S.; Taranova, A.G.; Protheroe, C.A.; Colbert, D.C., Lee, N.A.; Lee, J.J. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J. Exp. Med., 2008, 205, 699-710.
10. Stein, M.L.; Villanueva, J,M,; Buckmeier, B.K.; Yamada, Y.; Filipovich, A.H.; Assa'ad, A.H.; Rothenberg, M.E. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol. 2008, 121, 1473-1483
11. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol., 2008, 8, 183-192 (Pubitemid 351323287)
12. Bousquet, J.P.; Chanez, J.Y.; Lacoste, G.; Barneon, N.; Ghavanian, I.; Enander, P.; Venge, S.; Ahlstedt, J.; Simony-Lafontaine, P.; Godard, M.; Francois-Bernard Eosinophilic inflammation in asthma. N. Engl. J. Med., 1990, 323, 1033-1039.
13. Lee, J.J.; Dimina, D.; Macias, M.P.; Ochkur, S.I.; McGarry, M.P.; O'Neill, K.R.; Protheroe, C.; Pero, R.; Nguyen, T.; Cormier, S.A.; Lenkiewicz, E.; Colbert, D.; Rinaldi, L.; Ackerman, S.J.; Irvin, C.G.; Lee, N.A. Defining a link with asthma in mice congenitally deficient in eosinophils. Science, 2004, 305, 1773-1776
14. Humbles, A.A.; Lloyd, C.M.; McMillan, S.J.; Friend, D.S.; Xanthou, G.; McKenna, E.E.; Ghiran, S.; Gerard, N.P.; Yu, C.; Orkin, S.H.; Gerard, C. A critical role for eosinophils in allergic airways remodeling. Science, 2004, 305, 1776-1779 (Pubitemid 39249645)
15. Berger, W.E. New approaches to managing asthma: a US perspective. Therap. Clin. Risk Manag., 2008, 4, 363-379.
16. Foster, P.S; Rosenberg, H.F.; Asquith, K.L. Kumar, R.K. Targeting eosinophils in asthma. Curr. Mol. Med., 2008, 8, 585-590
17. Egan, R.W.; Umland, S.P.; Cuss, F.M.; Chapman, R.W. Biology of interleukin-5 and its relevance to allergic disease. Allergy, 1996, 51, 71-81. (Pubitemid 26174833)
18. Leckie, M.J; ten Brinke, A.; Khan, J.; Diamant, Z.; O'Conner, B.J.; Walls, C.M.; Mathur, A.K.; Cowley, H.C.; Chung, K.F.; Djukanovic, R.; Hansel, T.T.; Holgate, S.T.; Sterk, P.J.; Barnes, P.J.; Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hypersonsiveness and the late asthmatic response. Lancet, 2000, 356, 2144-2148
19. Flood-Page, P.T.; Menzies-Gow, A.N.; Kay, A.B.; Robinson, D. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med., 2003, 167, 199. (Pubitemid 36076080)
20. O'Byrne, P.M.; Inman, M.D.; Parameswaran, K. The trials and tribulations of IL-5, eosinophils and allergic asthma. J. Allergy Clin. Immunol., 2001, 108, 503-508 (Pubitemid 32978017)
21. O'Byrne, P.M. The demise of anti IL-5 for asthma, or not. Am. J. Respir. Crit. Care Med., 2007, 176, 1059-1060
22. Palframan, R.T.; Collins, P.D.; Williams, T.J.; Rankin, S.M. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood, 1998, 91, 2240.
23. Wenzel, S.E.; Schwartz, L.B.; Langmac, E.L.; Halliday, J.L.; Trudeau, J.B.; Gibbs, R.L.; Chu, H.W. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med., 1999, 160, 1001-1008
24. Balzar, S.; Chu, H.W.; Silkoff, P.; Cundall, M.; Trudeau, J.B.; Strand, M.; Wenzel, S. Increased TGF-beta2 in severe asthma with eosinophilia. J. Allergy Clin. Immunol., 2005, 115, 110. (Pubitemid 40075429)
25. Flood-Page, P.; Menzies-Gow, A.; Phipps, S.; Ying, S.; Wangoo, A.; Ludwig, M.S.; Barnes, N.; Robinson, D.; Kay, A.B. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest., 2003, 112, 1029-1036
26. Brightling, C.E.; Bradding, P.; Symon, F.A.; Holgate, S.T.; Wardlaw, A.J.; Pavord, I.D. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med., 2002, 346, 1699-1705. (Pubitemid 34547483)
27. Jatakanon, A.; Lim, S.; Barnes P.J. Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med., 2000, 161, 64-72.
28. Deykin, A.; Lazarus, S.C.; Fahy, J.V.; Wechsler, M.E.; Boushey, H.A.; Chinchilli, V.M.; Craig, T.J.; Dimango, E.; Kraft, M.; Leone, F.; Lemanske, R.F.; Martin, R.J.; Pesola, G.R.; Peters, S.P.; Sorkness, C.A.; Szefler, S.J.; Israel, E. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J. Allergy Clin. Immunol., 2005, 115, 720-727 (Pubitemid 40460845)
29. Jayaram, L.; Pizzichini, M.M.; Cook, R.J.; Boulet, L.P.; Lemière, C.; Pizzichini, E.; Cartier, A.; Hussack, P.; Goldsmith, C.H.; Laviolette, M.; Parameswaran, K.; Hargreave, F.E. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 2006, 27, 483-494 (Pubitemid 43372521)
30. Green, R.H.; Brightling, C.E.; McKenna, S.; Hargadon, B.; Parker, D.; Bradding, P.; Wardlaw, A.J.; Pavord, I.D. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360, 1715-1721 (Pubitemid 35447900)
31. Petsky, H.L.; Kynaston, J.A.; Turner, C.; Li, A.M.; Cates, C.J.; Lasserson, T.J.; Chang, A.B. ailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst. Rev., 2007, 18, CD005603.
32. Haldar, P.; Brightling, C.E.; Hargadon, B.; Gupta, S.; Monteir, W.; Sousa, A.; Marshall, R.P.; Bradding, P.; Green, R.H.; Wardlaw, A.J.; Pavord, I.D. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med., 2009, 360, 973-984
33. Nair, P.; Pizzichini, M.M.; Kjarsgaard, M.; Inman, M.D.; Efthimiadis, A.; Pizzichini, E.; Hargreave, F.E.; O'Byrne, P.M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med., 2009, 360, 985-993
34. Chusid, M.J.; Dale, D.C.; West, B.C.; Wolff, S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore), 1975, 54, 1-27.
35. Roufosse, F.E.; Goldman, M.; Cogan, E. Hypereosinophilic syndromes. Orphanet. J. Rare Dis., 2007, 2, 37.
36. Gleich, G.J.; Leiferman, K.M. The hypereosinophilic syndromes: current concepts and treatments. Br. J. Haematol., 2009, 145, 271-285
37. Rothenberg, M.E.; Klion, A.D.; Roufosse, F.E.; Kahn, J.E.; Weller, P.F.; Simon, H.U.; Schwartz, L.B.; Rosenwasser, L.J.; Ring, J.; Griffin, E.F.; Haig, A.E.; Frewer, P.I.; Parkin, J.M. Gleich, G.J. Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med., 2008, 358, 1215-1228
38. Plotz, S.G.; Simon, H.U.; Darsow, U.; Simon, D.; Vassina, E.; Yousefi, S.; Hein, R.; Smith, T.; Behrendt, H.; Ring, J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med., 2003, 349, 2334-2339. (Pubitemid 37521232)
39. De Angelis, P.; Morino, G.; Pane, A.; Torroni, F.; Francalanci, P.; Sabbi, T.; Foschia, F.; Caldaro, T.; di Abriola, G.F.; Dall'Oglio, L. Eosinophilic esophagitis: management and pharmacotherapy. Expert Opin. Pharmacother., 2008, 9, 731-740
40. Blanchard, C.; Rothenberg, M.E. Basic pathogenesis of eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am., 2008, 18, 133-143
41. Blanchard, C.; Wang, N.; Stringer, K.F.; Mishra, A.; Fulkerson, P.C.; Abonia, J.P.; Jameson, S.C.; Kirby, C.; Konikoff, M.R.; Collins, M.H.; Cohen, M.B.; Akers, R.; Hogan, S.P. Assa'ad, A.H.; Putnam, P.E.; Aronow, B.J. Rothenberg, M.E. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest., 2006, 116, 536-547.
42. Liu, L.Y.; Sedgwick, J.N; Bates, M.E; Vrtis, R.F.; Gern J.E; Kita, H. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process, J. Immunol., 2002, 169, 6459-6466. (Pubitemid 36903496)
43. Gevaert, P; Bachert, C; Holtappels, G; Novo, C.P.; Van der Heyden, J.; Fransen, L. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy, 2003, 58, 371-379. (Pubitemid 36605724)
44. Stein, M.L.; Collins, M.H.; Villanueva, J.M.; Kushner, J.P.; Putnam, P.E.; Buckmeier, B.K.; Filipovich, A.H.; Assa'ad, A.H.; Rothenberg, M.E. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol., 2006, 118, 1312-1319
45. Gevaert, P.; Lang-Loidolt, D.; Lackner, A.; Stammberger, H.; Staudinger, H.; Van Zele, T.; Holtappels, G.; Tavernier, J.; van Cauwenberge, P.; Bachert, C. IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol., 2006, 118, 1133-1141. (Pubitemid 44666979)
46. Oldhoff, J.M.; Darsow, U.; Werfel, T.; Katzer, K.; Wulf, A.; Laifaoui, J.; Hijnen, D.J. Plötz.; Knol, E.F.; Kapp, A.; Bruijnzeel-Koomen, C.A.; Ring, J.; de Bruin-Weller, M.S. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy, 2005, 60, 693-696